IRIDEX ANNOUNCES RETIREMENT OF VP FINANCE
March 30 2020 - 4:05PM
IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative
ophthalmic laser-based medical products for the treatment of
glaucoma and retinal diseases, announced today that Romeo Dizon has
retired from his position as Vice President of Finance, effective
March 27, 2020. Mr. Dizon has agreed to continue to serve as needed
as a consultant to facilitate a smooth transition and to provide
additional support through the end the Company’s first quarter 2020
reporting cycle.
IRIDEX’s Board of Directors has appointed James Mackaness to
serve as interim Chief Financial Officer while it searches for a
successor to Mr. Dizon. Mr. Mackaness previously served as IRIDEX’s
Chief Operating Officer from August 2012 to August 2015 and as the
Company’s Chief Financial Officer from January 2008 to August 2012.
He is currently a partner with FLG Partners, a leading Silicon
Valley CFO services and board advisory consultancy firm, and also
currently serves as Chief Financial Officer for Soleno
Therapeutics, a clinical-stage biopharmaceutical company. He was
previously Chief Financial Officer of Invuity, Inc., a medical
technology company, from August 2015 until its sale to Stryker
Corporation in October 2018.
“On behalf of everyone at IRIDEX and our Board of Directors, I
want to thank Romeo for his many contributions during his 12-year
tenure with the Company, including his strong leadership of our
financial organization over the past two years,” said David Bruce,
CEO of IRIDEX. “We appreciate his dedication and wish him all the
best beyond IRIDEX.”
“We are very pleased to welcome Jim Mackaness back to the IRIDEX
team. His proven skill set, coupled with in-depth knowledge of our
operations and internal processes, provides us great confidence
that we will experience seamless continuity in our financial
leadership,” concluded Bruce.
About IRIDEX
IRIDEX is a worldwide leader in developing innovative and
versatile laser-based medical systems, delivery devices and
consumable instrumentation for the ophthalmology market. The
Company’s proprietary MicroPulse® technology delivers a
differentiated treatment that provides safe, effective, and proven
treatment for targeted sight-threatening eye
conditions. IRIDEX’s current product line is used for the
treatment of glaucoma, diabetic macular edema (DME) and other
retinal diseases. IRIDEX products are sold in the United
States and Germany through a direct sales force and in more than
100 countries through a network of independent distributors. For
further information, visit the IRIDEX website at
http://www.iridex.com/.
Investor Relations Contact Leigh Salvo (415)
937-5404 investors@iridex.com
Media Contact Jamie Hall Pascale
Communications, LLC. (724) 417-0167 pr@iridex.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Apr 2024 to May 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From May 2023 to May 2024